Search: onr:"swepub:oai:DiVA.org:uu-299029" >
Impact of glycoprot...
-
Shimada, Yuichi J.Harvard Clin Res Inst, 930 Commonwealth Ave W, Boston, MA 02215 USA.;Harvard Univ, Brigham & Womens Hosp, Sch Med, Cardiovasc Div,Dept Med, Boston, MA 02115 USA.;Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
(author)
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes : Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial
- Article/chapterEnglish2016
Publisher, publication year, extent ...
-
Elsevier BV,2016
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-299029
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-299029URI
-
https://doi.org/10.1016/j.ahj.2016.03.015DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Background Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding. We evaluated whether the use of glycoprotein IIb/IIIa inhibitor (GPI) impacts the relative efficacy and safety of ticagrelor compared with clopidogrel. Methods PLATO randomized 18,624 subjects with acute coronary syndrome to ticagrelor versus clopidogrel. The primary efficacy end point was cardiovascular death/myocardial infarction/stroke, and the primary safety end point was major bleeding. The use of GPI was at the physician's discretion and open-label. We evaluated outcomes at 30 days stratified by GPI use in the subgroup of 9,983 patients who underwent percutaneous coronary intervention (PCI) within 72 hours. Results A total of 4,020 (40%) received a GPI. Those receiving a GPI were more likely to be younger, be male, and undergo multivessel PCI. There was no interaction between treatment and GPI use for the primary efficacy and safety end points. Patients treated without GPI had a lower rate of definite stent thrombosis and higher rate of minor/major bleeding with ticagrelor compared with clopidogrel (P<.05), whereas there was no such difference with GPI (P interaction <.05). Conclusions In patients with acute coronary syndrome undergoing early PCI, the efficacy and safety of ticagrelor as compared with clopidogrel were not modified by GPI use according to the primary efficacy and safety end point of the trial, although there were indications of greater benefit on definite stent thrombosis and more major or minor bleeding with ticagrelor in patients without (vs with) GPI treatment.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Bansilal, SameerIcahn Sch Med Mt Sinai, Cardiovasc Inst, New York, NY 10029 USA.
(author)
-
Wiviott, Stephen D.Harvard Univ, Brigham & Womens Hosp, Sch Med, Cardiovasc Div,Dept Med, Boston, MA 02115 USA.
(author)
-
Becker, Richard C.Univ Cincinnati, Coll Med, Heart Lung & Vasc Inst, Div Cardiovasc Hlth & Dis, Cincinnati, OH USA.
(author)
-
Harrington, Robert A.Stanford Univ, Dept Med, Stanford, CA 94305 USA.
(author)
-
Himmelmann, AndersAstraZeneca Res & Dev, Molndal, Sweden.
(author)
-
Neely, BenjaminDuke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
(author)
-
Husted, SteenHosp Unit West, Med Dept, Herning Holstebro, Denmark.
(author)
-
James, Stefan K.Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)(Swepub:uu)stjam367
(author)
-
Katus, Hugo A.Univ Klinikum Heidelberg, Med Klin, Heidelberg, Germany.
(author)
-
Lopes, Renato D.Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
(author)
-
Steg, Ph. GabrielINSERM, U1148, Paris, France.;Hop Bichat Claude Bernard, Dept Hosp Univ FIRE, AP HP, F-75877 Paris, France.;Univ Paris Diderot, Sorbonne Paris Cite, Paris, France.;NHLI Imperial Coll, Royal Brompton Hosp, ICMS, London, England.
(author)
-
Storey, Robert F.Univ Sheffield, Dept Cardiovasc Sci, Sheffield, S Yorkshire, England.
(author)
-
Wallentin, LarsUppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)(Swepub:uu)larswall
(author)
-
Cannon, Christopher P.Harvard Clin Res Inst, 930 Commonwealth Ave W, Boston, MA 02215 USA.;Harvard Univ, Brigham & Womens Hosp, Sch Med, Cardiovasc Div,Dept Med, Boston, MA 02115 USA.
(author)
-
Harvard Clin Res Inst, 930 Commonwealth Ave W, Boston, MA 02215 USA.;Harvard Univ, Brigham & Womens Hosp, Sch Med, Cardiovasc Div,Dept Med, Boston, MA 02115 USA.;Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.Icahn Sch Med Mt Sinai, Cardiovasc Inst, New York, NY 10029 USA.
(creator_code:org_t)
Related titles
-
In:American Heart Journal: Elsevier BV177, s. 1-80002-87031097-6744
Internet link
Find in a library
To the university's database
- By the author/editor
-
Shimada, Yuichi ...
-
Bansilal, Sameer
-
Wiviott, Stephen ...
-
Becker, Richard ...
-
Harrington, Robe ...
-
Himmelmann, Ande ...
-
show more...
-
Neely, Benjamin
-
Husted, Steen
-
James, Stefan K.
-
Katus, Hugo A.
-
Lopes, Renato D.
-
Steg, Ph. Gabrie ...
-
Storey, Robert F ...
-
Wallentin, Lars
-
Cannon, Christop ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cardiac and Card ...
- Articles in the publication
-
American Heart J ...
- By the university
-
Uppsala University